Koru Medical (KRMD) Q3 2026 earnings review
Koru Medical raises its outlook floor, but overseas orders slip
Koru Medical earned a profit for a second straight quarter on higher margins even as European launch timing slowed its sales growth. The maker of at-home infusion pumps and tubing grew revenue 11% to $11.6 million, while factory cost savings and tariff rebates lifted its gross margin by 5 percentage points to 65.2%. Chief executive Adam Kalbermatten raised the bottom of the full-year revenue outlook, which by our math requires sales growth to rebound to 18% in the fourth quarter.
| Normalized International Core sales | +23.2% -16.5% as reported, after a $1.2M prior-year distributor shift |
|---|---|
| Total revenue | $11.6M +11.2% from a year ago |
| Gross margin | 65.2% up 5.0 percentage points from a year ago |
| Full-year revenue outlook | Raised low end $0.5M middle of the range: 17.3% growth |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because durable margin gains and a higher full-year outlook floor offset a third-quarter cash outflow and slower overseas orders. Stripping out a prior-year distributor shift shows underlying international sales rose 23% from a year ago, though they still fell 11% from the second quarter. One caution: operations burned nearly $0.9 million of cash in the quarter by our math as inventory rose and bills came due, leaving work to do in the fourth quarter to hit the raised $8 million cash target.
The question now is whether overseas sales are building a steady base of repeat needle users or riding uneven distributor pump orders. If patients are converting onto Koru's pumps, international revenue will rebound alongside fourth-quarter cash collections; if distributors merely stocked shelves early, the fourth-quarter target will be tough to reach. Fourth-quarter international sales and year-end cash will tell.
🐂 Bull Case
Gross Margin Reached 65.2% on Factory Savings
Koru Medical makes mechanical pumps and tubing that let patients infuse liquid medicines under the skin at home. The company lifted its gross margin to 65.2% from 60.2% a year ago because the cost of making its products fell 5.0 percentage points of revenue. Management attributed the gain to "lower manufacturing costs, higher than average selling prices from our geographical customer mix and lower tariff costs driven by tariff related rebates".
The company also raised the bottom of its full-year gross margin outlook by one percentage point to a range of 63% to 64%. Because domestic sales carry higher prices than overseas distributor shipments, a quarter where US revenue made up 69.6% of total sales naturally helped the margin. Even so, clearing 65% for a second straight quarter shows that recent supplier price reductions are holding up.
What to watch: fourth-quarter gross margin, which the full-year outlook implies at about 62.3% at the middle of the range by our math. Holding above 63% without further tariff rebates would prove that factory savings alone can carry the margin as lower-priced international shipments recover.
Cost Discipline Kept Koru Profitable on Slower Growth
Chief executive Adam Kalbermatten said Koru delivered net income for a second consecutive quarter, calling it proof of a scalable business model. Operating margin rose 10.0 percentage points from a year ago to 1.6%, turning a $0.8 million net loss into a $0.2 million profit. Selling, general and administrative expenses — day-to-day overhead and sales pay — fell 6.9 percentage points of revenue to 50.7%, more than covering a 2.1-point rise in research and development spending.
What to watch: fourth-quarter operating expenses against the expected revenue step-up. Staying profitable on a standard reporting basis in the fourth quarter while funding new engineering hires from the recent technology acquisition would show the company can grow without returning to net losses.
Higher Revenue Floor Requires a Record Fourth Quarter
After third-quarter sales growth slowed to 11.2% from 18.2% in the second quarter, Kalbermatten said management continues to "anticipate revenue growth to reaccelerate in the fourth quarter for a strong finish to the year". To back that claim, the company raised the bottom of its full-year revenue outlook by $0.5 million to a range of $48.0 million to $48.5 million.
By our math, the middle of that updated plan leaves $12.9 million of revenue for the fourth quarter, which would be an all-time quarterly record and an 18.2% increase from a year ago. What to watch: fourth-quarter revenue against the $12.6 million low end implied by the outlook. Clearing that mark would confirm that European ordering delays in the third quarter were temporary.
Positives this quarter didn't test
Two longer-term growth initiatives received balance-sheet funding this quarter without new commercial milestones in the earnings release.
- Connected monitoring software: Koru recorded $0.2 million of capitalized software development costs and higher engineering payroll from its second-quarter technology purchase, and a dated pilot or launch plan on the conference call would test its commercial timeline.
- Secondary immunodeficiency label expansion: drug makers are running clinical trials that could expand Koru's addressable patient base over the next 12 to 18 months, and any trial readouts or partner updates on the call would move this driver.
🐻 Bear Case
European Launch Timing Pushed Overseas Sales Down Sequentially
Koru relies on European drug makers switching immunoglobulin medicines from glass vials to prefilled syringes to drive its overseas expansion. Kalbermatten said third-quarter growth slowed "reflecting in part the timing of our entry into a competitive non-tender market in Europe", and asserted that this market launch is now behind the company. A year ago, a US distributor bought roughly $1.2 million of product through an overseas partner, distorting both regional comparison bases.
- International Core revenue: $3.08 million, down 16.5% from a year ago as reported
- Normalized International Core growth: up 23.2% from a year ago after stripping out the $1.2 million distributor shift
- Sequential International Core move: down 11.1% from $3.47 million in the second quarter by our math
- Normalized Domestic Core growth: up 10.1% from a year ago, compared with 31.6% as reported
The sequential drop cuts against the framing of a smooth patient-by-patient ramp because existing overseas pumps should generate steady repeat orders for disposable tubing and needles. Although the company "Signed two new sales and distribution agreements with partners in Europe and Africa", third-quarter international sales fell $0.39 million from the second quarter. What to watch: fourth-quarter International Core revenue returning to the $3.5 million level from the second quarter, which would show that patient needle usage is catching up to earlier distributor pump shipments.
Cash Flow Turned Negative Despite Two Profitable Quarters
Koru highlighted its second straight quarter of positive net income and raised its year-end cash target to more than $8.0 million from more than $7.5 million. Yet cash on the balance sheet fell by $0.9 million during the third quarter to $7.36 million. By our math, subtracting first-half cash flows from the nine-month statement shows that operations burned $0.88 million of cash in the third quarter alone.
- Third-quarter operating cash flow: negative $0.88 million by our math, down from positive $0.22 million in the second quarter
- Nine-month accrued expenses outflow: $1.41 million used as the company paid down current bills and employee bonuses
- Nine-month inventory outflow: $1.01 million used as inventory rose 27.6% from year-end to $4.69 million
Adding $0.27 million of third-quarter equipment purchases by our math brings quarterly free cash flow to negative $1.15 million. Because cash sits at $7.36 million today, reaching the new $8.0 million year-end floor requires at least $0.64 million of net cash generation in the fourth quarter by our math. What to watch: fourth-quarter inventory and cash balances, where hitting the $8.0 million mark will require converting stocked pumps into customer cash collections.
Clinical Trial Orders Shrank for a Second Quarter
Through its Pharma Services and Clinical Trials unit, Koru customizes its infusion pumps and supplies devices to drug makers testing new injectable medicines. Revenue in this segment fell 27.4% from a year ago to $0.42 million, following a 35.0% drop in the second quarter. The company said a biopharmaceutical customer bought fewer products for a clinical trial program during the period.
While trial orders made up only 3.7% of third-quarter sales, they serve as the entry point for future commercial drug approvals beyond Koru's core immune-deficiency market. What to watch: fourth-quarter Pharma Services revenue and the count of new drug collaborations signed this year against the company's goal of four. Another decline would indicate that biotech partner consolidation is slowing down Koru's external drug pipeline.
Risks this quarter didn't answer
Four standing concerns from prior quarters received no new data in the third-quarter press release.
- Next-generation Freedom 360 pump filing: no regulatory submission date appeared in the release after the target moved from late 2026 to late 2027 last quarter; commentary on the call or in the quarterly filing will test whether the schedule held.
- US oncology replacement drug: after withdrawing its US application for the cancer drug Phesgo last quarter, Koru did not name a replacement medicine or filing date in the release.
- Distributor stocking versus patient usage: the release did not split overseas revenue between initial distributor pump orders and recurring needle sales, leaving distributor concentration risk untested.
- Undated long-term targets: management's previously stated goal of $100 million in revenue still lacks a target year or annual bridge.
👓 Other Themes
Tariff Rebates Helped Lift Third-Quarter Gross Margin
Import tariffs on medical device components had lowered Koru's gross margin in prior quarters, costing nearly one percentage point of margin earlier this year. In the third quarter, the infusion device maker reported that "lower tariff costs driven by tariff related rebates" contributed to its 5.0-percentage-point gross margin expansion, though the press release did not disclose the exact dollar size of the rebates or how many quarters they will last.
💲 Other KPIs
Stocked goods rose 27.6% from $3.68 million at the end of 2025 and grew 6.4% from a year ago by our math. Inventory has climbed in every quarter of 2026 — from $4.48 million in the first quarter to $4.51 million in the second — consuming $1.01 million of operating cash over the first nine months.
Uncollected customer bills rose 17.9% from $5.41 million a year ago and increased 6.9% from year-end 2025 by our math. Because receivables grew faster than the 11.2% rise in third-quarter revenue, delayed cash collections absorbed $0.41 million of operating cash across the first nine months of the year.
Diluted shares rose 1.1% from 46.24 million a year ago by our math, but fell from 49.51 million in the second quarter. During the first nine months, the medical device maker issued 125,628 shares of common stock to pay for $0.5 million of its connected-monitoring technology purchase and recorded $2.07 million in stock-based employee pay.
🔮 Guidance
Raised at the low end. The updated plan calls for 17% to 18% full-year growth, lifting the middle of the range by $0.25 million after a $0.75 million cut last quarter (+$0.0M, -$0.75M, +$0.25M). By our math, the middle of the range leaves $12.87 million for the fourth quarter, requiring growth to speed up to 18.2% from 11.2% this quarter.
Raised at the low end. The middle of the full-year target moved up 0.5 percentage points to 63.5%, marking the second raise this year (+0.0 pts, +1.0 pt, +0.5 pts). Because nine-month gross margin is already 64.0%, the full-year midpoint implies about 62.3% for the fourth quarter by our math, allowing for a higher share of lower-priced overseas shipments.
Unchanged. Management still calls for profit before interest, taxes, depreciation, and stock pay to remain above zero for the full year, without giving a dollar range. With $2.17 million already generated across the first nine months — including $1.31 million in the third quarter alone — Koru has cleared this floor with a wide buffer.
Raised. The infusion pump maker lifted its year-end cash floor by $0.5 million despite burning $0.9 million of cash in the third quarter. Because cash stood at $7.36 million on September 30, meeting the new floor requires adding at least $0.64 million of net cash in the fourth quarter by our math.
❓ Key Questions
How much did tariff rebates add to third-quarter gross margin?
Gross margin rose 5.0 percentage points to 65.2% partly on tariff rebates. Without the dollar amount of those rebates, investors cannot separate one-time duty refunds from permanent factory savings.
What drove the $0.88 million third-quarter operating cash outflow?
Koru reported positive net income and raised its year-end cash floor to $8.0 million, yet operations burned $0.88 million in the quarter by our math as accrued expenses fell and inventory rose.
How much of International Core revenue is recurring needle usage?
Overseas sales fell 11.1% from the second quarter to $3.08 million. Disclosing the split between one-time distributor pump stocking and repeat patient tubing orders would show whether European patient conversions are on track.
What are the filing dates for Freedom 360 and US oncology?
The press release gave no regulatory timeline for the next-generation Freedom 360 pump or a replacement US oncology drug after last quarter's schedule changes.